Plasma copeptin in children and adolescents with type 1 diabetes mellitus in comparison to healthy controls

Diabetes Research and Clinical Practice

Volumn 118, Issue , 2016, Pages 156-161

  Schiel, Ralf ^a   Perenthaler, Thomas Johannes ^a   Steveling, Antje ^b   Stein, Günter ^c  

^a MEDIGREIF Inselklinik Heringsdorf GmbH   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Education; HbA1c; Hypoglycaemia; Inflammation; Mother

Indexed keywords

C REACTIVE PROTEIN; COPEPTIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELANOMA ANTIGEN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOPEPTIDE;

ADOLESCENT; AGE; ALBUMINURIA; ARTICLE; BLOOD ANALYSIS; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SANDWICH IMMUNOASSAY; SOCIAL STATUS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; GLOMERULUS FILTRATION RATE; PATHOPHYSIOLOGY;

ADOLESCENT; BIOMARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHILD; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; MALE; TRIGLYCERIDES;

EID: 84976526515     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.06.019     Document Type: Article

References (25)

1. [1] Abbasi, A., Corpeleijn, E., Meijer, E., Postmus, D., Gansevoort, R.T., Gans, R.O.B., et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the prevention of renal and vascular endstage renal disease (PREVEND) study. Diabetologia 55 (2012), 1963–1970.
2. [2] American Diabetes Association, The expert committee on the diagnosis and classification of diabetes mellitus: report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997), 1183–1197.
3. [3] Arbeitsgemeinschaft Adipositas im Kindes- und Jugendalter (AGA). Leitlinien. Verabschiedet auf der Konsensus-Konferenz der AGA am 10.09.04. < http://www.a-g-a.de>, 04.04.2013.
4. [4] Bankir, L., Bouby, N., Ritz, E., Vasopressin: a novel target for the prevention and retardation of kidney disease?. Nat Rev Nephrol 9 (2013), 233–239.
5. [5] Bjornstad, P., Maahs, D.M., Diabetes comolications in childhood diabetes. New biomarkers and technologies. Curr Pediatr Rep 3 (2015), 177–186.
6. [6] Bortz, J., Statistik für Sozialwissenschaftler. 6th ed., 2005, Springer Verlag, Berlin, Germany.
7. [7] Enhörning, S., Wang, T.J., Nilsson, P.M., Almgreen, P., Hedblad, B., Berglund, G., et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 121 (2010), 2102–2108.
8. [8] Fenske, W., Stork, S., Blechschmidt, A., Maier, S.G., Morgenthaler, N.G., Allolio, B., Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 94 (2009), 123–129.
9. [9] Guidelines Subcommittee, 1999 World Health Organization – international society of hypertension guidelines for the management of hypertension. J Hypertens 17 (1999), 151–183.
10. [10] Hasslacher, C., Wolf, G., Kempe, P., Ritz, E., Diabetische nephropathie. Diabetologie 7 (2012), S99–S102.
11. [11] Hu, W., Ni, Y.J., Ma, L., Hao, H.R., Chen, L., Yu, W.N., Serum copeptin as a new biomarker in the early diagnosis of decline in renal function of type 2 diabetes mellitus patients. Int J Clin Exp Med 8 (2015), 9730–9736.
12. [12] Katan, M., Morgenthaler, N., Widmer, I., Puder, J.J., König, C., Müller, B., et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 29 (2008), 341–346.
13. [13] Meijer, E., Bakker, S.J., Halbesma, N., de Jong, P.E., Struck, J., Gansevoort, R.T., Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 77 (2010), 29–36.
14. [14] Meijer, E., Boertien, W., Zietse, R., Gansevoort, R., Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 34 (2011), 235–244.
15. [15] Meixner, K., Glattacker, M., Gerdes, N., Herwig, J., Bengel, J., Jäckel, W.H., Effects of treatment in mother-child rehabilitation centres. Rehabilitation (Stuttg) 40 (2001), 280–288.
16. [16] Morgenthaler, N.G., Struck, J., Alonso, C., Bergmann, A., Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52 (2006), 112–119.
17. [17] Mühlhauser, I., Hypoglykämie. Berger, M., (eds.) Diabetes mellitus, 2000, Urban Fischer, München, Germany, 370–386.
18. [18] Pikkemaat, M., Melander, O., Bengtsson Boström, K., Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J Diabetes Complications, 2015, 10.1016/j.jdiacomp.2015.07.006 pii: S1056-8727(15)00274-3, 07.10.2015.
19. [19] Saleem, U., Khaleghi, M., Morgenthaler, N.G., Bergmann, A., Struck, J., Mosley, T.H., et al. Plasma carboxy-terminal pro-vasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 94 (2009), 2558–2564.
20. [20] Spruce, B.A., McCulloch, A.J., Burd, J., Orskov, H., Heaton, A., Baylis, P.H., et al. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol 22 (1985), 463–468.
21. [21] Szinnai, G., Morgenthaler, N.G., Berneis, K., Struck, J., Müller, B., Keller, U., et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 92 (2007), 3973–3978.
22. [22] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
23. [23] Van Gastel, M.D.A., Meijer, E., Scheven, L.E., Struck, J., Bakker, S.J.L., Gansevoort, R.T., Modifiable factors associated with copeptin concentrations: a general population cohort. Am J Kidney Dis 65 (2015), 719–727.
24. [24] Yalta, K., Yalta, T., Sivri, N., Yetkin, E., Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 167 (2013), 1750–1759.
25. [25] Zerbe, R.L., Vinicor, F., Robertson, G.L., Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28 (1979), 503–508.